SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-137689
Filing Date
2023-05-08
Accepted
2023-05-08 07:41:59
Documents
14
Period of Report
2023-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d439043d8k.htm   iXBRL 8-K 25467
2 EX-99.1 d439043dex991.htm EX-99.1 51610
6 GRAPHIC g439043g89r49.jpg GRAPHIC 5005
  Complete submission text file 0001193125-23-137689.txt   213537

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akba-20230508.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20230508_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20230508_pre.xml EX-101.PRE 10809
8 EXTRACTED XBRL INSTANCE DOCUMENT d439043d8k_htm.xml XML 3279
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 23895880
SIC: 2834 Pharmaceutical Preparations